Dr. Martin Prlic is a Professor in the Vaccine and Infectious Disease Division at Fred Hutch Cancer Center. He discusses the challenges of studying human immunology and how his lab uses advanced single-cell technologies to understand T cell responses across healthy, inflamed, and tumor tissues. He also explores the biology of tissue-resident T cells, how inflammation shapes their function, and immune cell interactions at the maternal-fetal interface.
lncRNA Regulates Gut Immunity – An IBD-associated long noncoding RNA promotes immune tolerance by enhancing regulatory T cell function and limiting inflammatory T cell responses.
Trust in Research Antibodies – An investigation identified nearly 19,000 apparently manipulated antibody validation images across products sold by 15 research antibody vendors.
Targeting Melanoma with mRNA – A Phase III trial found that a personalized mRNA neoantigen therapy combined with KEYTRUDA improved recurrence-free and distant metastasis-free survival compared with KEYTRUDA alone after melanoma surgery.
Beyond Shingles Prevention – A recombinant shingles vaccine was associated with a lower long-term risk of several cardiovascular outcomes, supporting further studies of its potential cardioprotective effects.
Engineering Myeloid Immunotherapy – Expandable granulocyte-monocyte progenitors provide a scalable platform for engineering macrophages that can target blood and solid tumors.
CAR T Cells Meet Glioblastoma – Responses to CAR T cell therapy for glioblastoma are associated with the surrounding immune environment, with NK cells linked to response and regulatory T cells and suppressive myeloid cells linked to resistance.
Image courtesy of Dr. Martin Prlic